Screener
Royalty Pharma RPRX Allowance for Credit Losses - Receivable (Current)
Allowance for Credit Losses - Receivable (Current) at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:FinancingReceivableAllowanceForCreditLosses.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
FAQ
- What is Royalty Pharma's allowance for credit losses - receivable (current)?
- Royalty Pharma (RPRX) reported allowance for credit losses - receivable (current) of $3.04B in Q2 2026.
- How has Royalty Pharma's allowance for credit losses - receivable (current) changed year-over-year?
- Royalty Pharma's allowance for credit losses - receivable (current) decreased by 12.2% year-over-year, from $3.46B to $3.04B.
- What is the long-term trend for Royalty Pharma's allowance for credit losses - receivable (current)?
- Over 5 years (2020 to 2025), Royalty Pharma's allowance for credit losses - receivable (current) has grown at a 21.9% compound annual growth rate (CAGR), from $1.26B to $3.4B.
- What does allowance for credit losses - receivable (current) mean?
- The estimated amount of accounts receivable that may not be collected within the current period, specifically related to credit losses.
Ask your AI about Royalty Pharma's allowance for credit losses - receivable (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude